Form 4: Whitehawk Therapeutics Executive Equity Transactions

Bryan Ball, Chief Technical Operations Officer at Whitehawk Therapeutics, reported significant equity transactions including the acquisition of restricted stock units and stock options.

Summary

• Bryan Ball, Chief Technical Operations Officer and SVP of Manufacturing Operations at Whitehawk Therapeutics, Inc., reported transactions related to his beneficial ownership of company stock.
• On April 1, 2026, Mr. Ball acquired 366,532 Restricted Stock Units (RSUs).
• These RSUs represent a contingent right to receive one share of Whitehawk Therapeutics, Inc. Common Stock.
• The RSUs are subject to vesting conditions, with 100% vesting on the one-year anniversary of the Vesting Commencement Date of April 1, 2025.
• Mr. Ball also acquired a stock option on April 1, 2026, granting him the right to buy 250,058 shares of common stock at an exercise price of $3.54.
• This stock option vests over four years, with 25% vesting on the one-year anniversary of the Vesting Commencement Date of April 1, 2026, and the remainder vesting monthly thereafter.
• Following these transactions, Mr. Ball beneficially owns 572,551 shares of common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it details standard executive equity grants rather than significant financial performance or strategic shifts that would strongly influence investor sentiment.

Positives

• Acquisition of a significant number of RSUs (366,532) indicates continued commitment and potential future value realization for a key executive.
• Granting of stock options (250,058) aligns executive interests with long-term shareholder value creation.
• Clear vesting schedules for both RSUs and stock options provide transparency and incentivize continued service.

Negatives

• The filing details equity grants rather than direct purchases of stock, which may not immediately signal strong personal conviction in short-term stock performance.
• Vesting is contingent on continued service, meaning the full value is not immediately realized and could be forfeited if employment ceases.

Risks

• The vesting of RSUs and stock options is contingent upon the Reporting Person continuing to be a Service Provider, implying a risk of forfeiture if employment is terminated.
• The stock option exercise price of $3.54 suggests that the stock price needs to appreciate significantly beyond this level for the option to be profitable.

Future Outlook

The vesting schedules for the RSUs and stock options indicate a forward-looking incentive structure tied to continued employment and potential future stock price appreciation.

Management Comments

• The filing is a statement of changes in beneficial ownership and does not contain direct management comments or quotes.
• The 'Explanation of Responses' section details the terms of the RSU and stock option awards, providing clarity on their structure and vesting.

Industry Context

StockSavvy.ai notes that the issuance of RSUs and stock options to executives is a common practice in the biotechnology and pharmaceutical sectors to attract, retain, and incentivize key personnel, aligning their interests with long-term company performance and shareholder value.

Stakeholder Impact

• Shareholders: The equity grants align executive interests with long-term shareholder value, but the immediate impact on share price is minimal. Dilution is a potential long-term consideration as options are exercised.
• Employees: The grants to a senior executive may reflect the company's overall compensation strategy, potentially influencing morale and retention across the organization.
• Management: Bryan Ball's compensation is directly tied to his continued service and the company's future performance, as evidenced by the vesting conditions.

Next Steps

• Vesting of RSUs on April 1, 2026.
• Monthly vesting of stock options commencing after April 1, 2026.
• Continued service by Bryan Ball as Chief Technical Operations Officer and SVP, Manufacturing Operations.

Key Dates

Keywords

Form 4, SEC Filing, Whitehawk Therapeutics, Bryan Ball, Equity Transaction, Restricted Stock Units, Stock Options, Beneficial Ownership, Executive Compensation, Insider Trading